Market Intelligence, Clinical Progress, and High-Purity Reagents for ETV6-related Malignancies and Fusion-Driven Oncogenesis.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ETV6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ETV6 Recombinant Protein (Full-Length & Functional Domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ETV6 Products |
| Gene Delivery | ETV6 Promise-ORF / Lentivirus Full-length ORF and fusion constructs (e.g., ETV6-NTRK3) for stable cell line generation. |
View ETV6 Products |
| Benchmark Ab | Anti-ETV6 Recombinant Antibody Recombinant positive control for Western Blot, IP, and IHC. |
View ETV6 Products |
| Validator | ETV6 siRNA Set For target knockdown verification and functional validation. |
View ETV6 Products |
| Related Target A | NTRK3 Key fusion partner forming the oncogenic ETV6-NTRK3 chimera in secretory breast carcinoma and infantile fibrosarcoma. |
View NTRK3 Products |
| Related Target B | JAK2 Fusion partner forming ETV6-JAK2, a driver of atypical chronic myeloid leukemia (aCML) and acute lymphoblastic leukemia (ALL). |
View JAK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Access & Transcription Factor Complexing | High-purity ETV6 Point (PNT) and ETS domains expressed in native conformation for biophysical interaction assays. |
| Fusion-Specific Epitope Screening | Custom-designed junction-peptide antigens and recombinant fusion proteins covering clinical breakpoint sequences. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies and recombinant positive controls included. |
| False Positives in Knockdown Studies | Chemically synthesized siRNA pools validated for specific ETV6 mRNA transcript depletion. |
Live ETV6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of ETV6 is rapidly evolving. Historically known as a recurrent fusion partner in hematological and solid tumors (such as ETV6-NTRK3 and ETV6-RUNX1), ETV6 is transitioning from an "undruggable" transcription factor to a high-value target for novel modalities. Current clinical strategies are shifting from downstream kinase inhibition (e.g., TRK inhibitors) to direct disruption of ETV6 transcriptional complexes and targeted protein degradation (PROTACs/molecular glues).
As first-generation kinase inhibitors face mutational resistance, the next wave of R&D is targeting the ETV6 oligomerization domain (PNT domain) and utilizing targeted protein degraders to eliminate the oncogenic chimeric proteins entirely.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Arvinas, Kymera Therapeutics, Academic Labs | Leukemias (ALL, AML), Solid Tumors | Degradation kinetics assay (Requires high-purity ETV6 proteins & Lentivirus for reporter cell lines) |
| Small Molecule (Inhibitor) | Bayer, Loxo Oncology (Eli Lilly) | NTRK/JAK Fusion-positive Cancers | Selectivity assays (Need mutant vs wild-type fusion proteins to screen bypass resistance) |
| RNA Therapeutics | Alnylam, Ionis Pharmaceuticals | Refractory Hematological Malignancies | In vitro knockdown validation (Requires validated ETV6 siRNA sets) |